Targets › RIG1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2029.
Exhibits both phospholipase A1/2 and acyltransferase activities. Shows phospholipase A1 (PLA1) and A2 (PLA2), catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids. (UniProt, Q9UL19)
Open in Phaseline: the race on RIG1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Adilia Hormigo | Poly-ICLC (Hiltonol®) Toll-like receptor 3 (TLR3) agonist and RIG-I-like receptor agonist - immune adjuvant | TLR3, RIG1 | Phase 1 | Glioblastoma | May 2029 |
Glioblastoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.